The results showed that the expression level of STC2 was significantly different among 27 tumors, except breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), esophageal carcinoma (ESCA), stomach and esophageal carcinoma (STES), bladder urothelial carcinoma (BLCA), acute lymphoblastic leukemia (ALL), and pheochromocytoma and paraganglioma (PCPG) (Figure 3E). This evidence concerns the gene STC2 and acute lymphoblastic leukemia.